Are there any clinical scenarios in which you would treat BRCA mutated HER2 negative metastatic breast cancer with a PARP inhibitor in combination with carboplatin?
Do any studies support this rationale? Does the presence of a somatic vs germline BRCA mutation impact your decision?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
There is a large prospective phase III study that showed a significant improvement in DFS for veliparib+carbo+ paclitaxel versus carbo+paclitaxel (BROCADE3 study; Dieras V et., PMID 32861273).
Join for free or sign in to see the full answer